Value Proposition: Advantages: • Uses known natural chemicals to effectively prevent or diminish skin blistering • Represents a safe, effective, and affordable therapy • Has a wider application as the basis for a therapy of keratin-based diseases
Technical Details:
Epidermolysis bullosa is a disorder characterized by the presence of extremely fragile skin, which loses its integrity after trivial mechanical trauma. The symptoms of this disease vary from minor to severe with widespread blistering that can lead to infections, dehydration, and other medical problems. It can be severe enough to result in neonatal or infant death. Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa. Currently, management of all types of EBS consists of palliative methods and has limited success. Therefore, there is a need for improved treatment of EBS. JHU researchers have discovered that a small molecule, which is a Nrf2-inducer and naturally present in the diet, significantly decreased the massive (lethal) skin blistering in a mouse model of EBS.
Looking for Partners:
Development of a topical ointment that would be applied directly on the skin over relevant portions of the body to prevent or minimize skin blistering resulting from frictional trauma.
Publications/Associated Cases:
